Eledon Pharmaceuticals Inc. Registered Shares DL -,001
- BID
3.44
- ASK
3.46
- 17,442 Units2,890 Units
- 07/21, 21:59:26 PM
Sector and Industry
Healthcare, Biopharmaceuticals
Performance (1Y)
8.33%
Market Cap
-
P/E Ratio
0.00
Dividend Yield
0.00 %
Earnings per Share
-0.49 €
Peer Group
| Company Name | Market Cap | Revenue Last Reported Year | P/E Ratio | Profit Growth 1Y | Last Price | Previous Trading Day Change |
|---|---|---|---|---|---|---|
| Eli Lilly and Company | 864.54 Bil. | 57.78 Bil. | 46.82 | +86.88 % | 0.00 | - |
| Johnson & Johnson | 425.70 Bil. | 83.48 Bil. | 18.82 | +82.71 % | 0.00 | - |
| AbbVie Inc. | 343.94 Bil. | 54.21 Bil. | 96.78 | -5.29 % | 0.00 | - |
| Roche Holding AG | 286.62 Bil. | 65.80 Bil. | 20.72 | +58.45 % | 0.00 | - |
| AstraZeneca PLC | 244.91 Bil. | 52.09 Bil. | 27.55 | +39.41 % | 0.00 | - |
| NOVARTIS AG | 224.76 Bil. | 48.44 Bil. | 18.30 | +12.45 % | 0.00 | - |
| Merck & Co. Inc. | 221.79 Bil. | 57.55 Bil. | 14.46 | +2.25 % | 0.00 | - |
| Novo-Nordisk AS B | 193.52 Bil. | 41.49 Bil. | 14.11 | +1.54 % | 0.00 | - |
| Amgen Inc. | 150.16 Bil. | 32.57 Bil. | 23.01 | +80.77 % | 0.00 | - |
| Gilead Sciences Inc. | 129.70 Bil. | 26.10 Bil. | 18.10 | +1,599.93 % | 0.00 | - |
Facts & figures
Price data
| TRADE PLATFORM | Börse Stuttgart (XSTU) | |
| LAST PRICE | 3.46 G | 0 Units |
| PRICE DETERMINATION TIME | 07/21/2026 / 09:56:52 PM | |
| DAILY VOLUME (UNITS) | 0 | |
| DAILY HIGH / LOW | 3.5 | 3.38 |
| PREV. DAY'S PRICE | 3.38 | (07/20) |
| CHANGE DAY BEFORE | +0.08 | 2.37 % |
| 52 WEEK HIGH / LOW | 3.72 (10/31) | 1.19 (01/02) |
Key Figures (in EUR)
| 2023 | 2024 | 2025 | 2026e | 2027e | |
|---|---|---|---|---|---|
EARNINGS PER SHARE | -4.38 | -0.69 | -0.49 | -0.80 | -0.65 |
DIVIDENDS PER SHARE | 0.00 | 0.00 | 0.00 | - | - |
DIVIDEND YIELD IN % | 0.00 % | 0.00 % | 0.00 % | - | - |
DIVIDEND GROWTH IN % | - | - | - | - | - |
PRICE - EARNINGS RATIO | - | - | - | - | - |
PRICE - BOOK RATIO | 6.05 | 2.09 | 1.40 | - | - |
PRICE - SALES RATIO | - | - | - | - | - |
PRICE - CASH FLOW RATIO | - | - | - | - | - |
Master Data
| WKN | A2QL00 |
| ISIN | US28617K1016 |
| SYMBOL | 2TK |
| EXCHANGE SEGMENT | Freiverkehr |
| TYPE OF FINANCIAL INSTRUMENT | Equity |
| DENOMINATION | ELEDON PHARMACEUT.DL-,001 |
| INDEX MEMBERSHIP | - |
| TRADING SEGMENT | - |
| TRADING HOURS | 07:30:00 AM - 10:00:00 PM |
| TRADING CURRENCY | Euro |
| NOMINAL CURRENCY | - |
| SETTLEMENT CURRENCY | Euro |
| SECTOR AND INDUSTRY | Healthcare, Biopharmaceuticals |
| NUMBER OF SHARES | - |
| MARKET CAPITALISATION | - |
Performance overview
| 1W | 1M | 3M | 6M | 1Y | 3Y | 5Y | YTD | |
|---|---|---|---|---|---|---|---|---|
| PERFORMANCE | 0.60 % | 1.20 % | -1.74 % | 89.89 % | 8.33 % | - | - | 160.00 % |
| HIGH | 3.68 | 3.72 | 3.72 | 3.72 | 3.72 | - | - | 3.72 |
| LOW | 3.24 | 3.14 | 2.78 | 1.52 | 1.19 | - | - | 1.19 |
Dividende
pro Aktie
ELEDON PHARMACEUT.DL-,001 does not deliver dividend information
Company profile
Eledon Pharmaceuticals, Inc. is a clinical stage biotechnology company, which engages in development of therapies to protect transplanted organs and prevent rejection. The firm also focuses on development of therapy to treat amyotrophic lateral sclerosis. Its compound in development is tegoprubart, a humanized IgG1 anti-CD40L antibody with high affinity for CD40 ligand (CD40L), a biological target with broad therapeutic potential. The company was founded on March 26, 2004 and is headquartered in Irvine, CA.
Analyst Rating
Ø-Target Price DistanceNot Available
Current Price
Not AvailableØ-Target Price
Not AvailableAverage ResultNot Available
Buy0
Overweight0
Hold0
Underweight 0
Sell0
Company Events
No company events available.